AstraZeneca (AZN) and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu (trastuzumab deruxtecan) in breast cancer.The regulatory body has now approved Enhertu as a monotherapy for treating metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for the therapy as the next line of treatment in the European Union (“EU”).The la ...

Group 1 - AstraZeneca achieved a remarkable 18% increase in revenue, reaching record levels in 2024 [1] - The growth in revenue was primarily driven by strong performance in key therapeutic areas [1] Group 2 - AstraZeneca is recognized as one of the pillars of the global pharmaceutical industry [1]

Signage at the AstraZeneca facility in Gaithersburg, Maryland, US, on Monday, Aug. 26, 2024. He said that leads to 4 million to 5 million deaths worldwide due to elevated cholesterol. While PCSK9 injections have helped treatment reach more patients, their use has still been "very limited," Makar said. That's due to several factors, such as challenges related to cost and access and hesitancy among some cardiologists and primary care physicians. "That's why we're really excited about our oral PCSK9," Makar sa ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registrant ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy, resulting in heart failure.AstraZeneca Plc‘s AZN Alexion will be responsible ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Astrazeneca (AZN) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Astrazeneca currently has an av ...

Core Insights - Lunit is set to present a deep learning study on predicting EGFR mutations in non-small cell lung cancer (NSCLC) at the AACR Annual Meeting 2025, showcasing the Lunit SCOPE Genotype Predictor in collaboration with AstraZeneca [1][2] Group 1: Study Details - The study utilizes the largest and most diverse training dataset to date, comprising over 12,000 pathology slides, including more than 4,500 EGFR-mutated and over 7,500 wild-type samples from NSCLC patients across multiple countries [3] - The AI model demonstrated consistent performance across various clinical variables, including specimen types, EGFR mutation subtypes, slide scanners, and scan magnifications, indicating its potential for real-world application [4] Group 2: Industry Impact - The collaboration aims to enhance the efficiency of EGFR mutation testing, which is critical for determining treatment options for NSCLC patients, addressing logistical and resource constraints that have previously limited testing [3][5] - The successful application of AI in this context could enable clinicians to prioritize molecular testing, ensuring timely access to targeted therapies for patients [5] Group 3: Company Background - Lunit, founded in 2013, focuses on AI-powered medical image analytics and biomarker analysis to improve cancer diagnosis and treatment, with its FDA-cleared Lunit INSIGHT suite serving over 4,800 medical institutions globally [7] - The company has a strong presence in the medical community, with clinical studies published in prestigious journals and presented at major global conferences [7]

Core Viewpoint - AstraZeneca has shown strong financial performance despite facing challenges, making it a potentially attractive investment opportunity for long-term holders [2][4][5]. Financial Performance - AstraZeneca's revenue increased by 18% year over year to $54.1 billion, with adjusted earnings per share rising 13% to $8.21 [4]. - The company has a diversified lineup, with 14 medicines each generating over $1 billion in sales last year [9]. Challenges and Risks - AstraZeneca faced executive arrests and an insurance fraud investigation in China, which impacted its stock price [3][5]. - The company may incur fines related to illegal drug importation in China, potentially amounting to $4.5 million, which is manageable given its revenue scale [6]. - Two patent expirations in the U.S. for Soliris and Brilinta are anticipated, but their impact on overall growth is expected to be minimal [7][8]. Growth Potential - AstraZeneca's pipeline includes promising new therapies, such as the investigational oral GLP-1 therapy AZD5004, which is in early clinical trials [10]. - The company is actively pursuing various therapeutic areas, with over a dozen regulatory approvals or clinical trial readouts expected [11]. Investment Outlook - Despite short-term headwinds, AstraZeneca's stock has performed well, indicating investor confidence [12].

Outside the Macclesfield factory of AstraZeneca.British pharmaceutical giant AstraZeneca on Friday said that it will invest $2.5 billion in a research and development center in Chinese capital Beijing.The new hub is expected to take AstraZeneca's Beijing workforce to around 1,700 employees.Don't miss AstraZeneca's CEO Pascal Soriot interview live on CNBC International at 11:30 a.m. London time / 7:30 a.m. ET.This breaking news story is being updated. ...

AstraZeneca (AZN) recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) as monotherapy for treating limited-stage small cell lung cancer (LS-SCLC) in adult patients whose disease has not progressed following platinum-based chemoradiation therapy (CRT).The latest approval for Imfinzi in the European Union (EU) was based on data from the phase III ADRIATIC study.Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of ...